Literature DB >> 31412117

Cooperation of oncolytic virotherapy with VEGF-neutralizing antibody treatment in IDH wildtype glioblastoma depends on MMP9.

Hans-Georg Wirsching1,2, Sonali Arora1,3, Huajia Zhang4, Frank Szulzewsky1, Patrick J Cimino1,5, Christophe Quéva6, A McGarry Houghton4, Joseph C Glorioso7, Michael Weller2, Eric C Holland1,4,8,9.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31412117      PMCID： PMC6917394          DOI： 10.1093/neuonc/noz145

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   13.029


× No keyword cloud information.
  6 in total

1.  Arming oHSV with ULBP3 drives abscopal immunity in lymphocyte-depleted glioblastoma.

Authors:  Hans-Georg Wirsching; Huajia Zhang; Frank Szulzewsky; Sonali Arora; Paola Grandi; Patrick J Cimino; Nduka Amankulor; Jean S Campbell; Lisa McFerrin; Siobhan S Pattwell; Chibawanye Ene; Alexandra Hicks; Michael Ball; James Yan; Jenny Zhang; Debrah Kumasaka; Robert H Pierce; Michael Weller; Mitchell Finer; Christophe Quéva; Joseph C Glorioso; A McGarry Houghton; Eric C Holland
Journal:  JCI Insight       Date:  2019-07-11

2.  Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial.

Authors:  Michael Weller; Nicholas Butowski; David D Tran; Lawrence D Recht; Michael Lim; Hal Hirte; Lynn Ashby; Laszlo Mechtler; Samuel A Goldlust; Fabio Iwamoto; Jan Drappatz; Donald M O'Rourke; Mark Wong; Mark G Hamilton; Gaetano Finocchiaro; James Perry; Wolfgang Wick; Jennifer Green; Yi He; Christopher D Turner; Michael J Yellin; Tibor Keler; Thomas A Davis; Roger Stupp; John H Sampson
Journal:  Lancet Oncol       Date:  2017-08-23       Impact factor: 41.316

Review 3.  Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa.

Authors:  Kabir A Khan; Robert S Kerbel
Journal:  Nat Rev Clin Oncol       Date:  2018-02-13       Impact factor: 66.675

4.  Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors.

Authors:  Sunyoung Lee; Shahla M Jilani; Ganka V Nikolova; Darren Carpizo; M Luisa Iruela-Arispe
Journal:  J Cell Biol       Date:  2005-05-23       Impact factor: 10.539

Review 5.  Oncolytic Viruses in Cancer Treatment: A Review.

Authors:  Sean E Lawler; Maria-Carmela Speranza; Choi-Fong Cho; E Antonio Chiocca
Journal:  JAMA Oncol       Date:  2017-06-01       Impact factor: 31.777

6.  Autocrine VEGFR1 and VEGFR2 signaling promotes survival in human glioblastoma models in vitro and in vivo.

Authors:  Emese Szabo; Hannah Schneider; Katharina Seystahl; Elisabeth Jane Rushing; Frank Herting; K Michael Weidner; Michael Weller
Journal:  Neuro Oncol       Date:  2016-03-23       Impact factor: 12.300
  6 in total
  5 in total

Review 1.  The complex relationship between integrins and oncolytic herpes Simplex Virus 1 in high-grade glioma therapeutics.

Authors:  Kimberly Ann Rivera-Caraballo; Mitra Nair; Tae Jin Lee; Balveen Kaur; Ji Young Yoo
Journal:  Mol Ther Oncolytics       Date:  2022-06-06       Impact factor: 6.311

Review 2.  Leveraging the replication-competent avian-like sarcoma virus/tumor virus receptor-A system for modeling human gliomas.

Authors:  Pranjali P Kanvinde; Adarsha P Malla; Nina P Connolly; Frank Szulzewsky; Pavlos Anastasiadis; Heather M Ames; Anthony J Kim; Jeffrey A Winkles; Eric C Holland; Graeme F Woodworth
Journal:  Glia       Date:  2021-02-27       Impact factor: 7.452

3.  Plasmatic MMP9 released from tumor-infiltrating neutrophils is predictive for bevacizumab efficacy in glioblastoma patients: an AVAglio ancillary study.

Authors:  Carine Jiguet-Jiglaire; Sebastien Boissonneau; Emilie Denicolai; Victoria Hein; Romain Lasseur; Josep Garcia; Sylvie Romain; Romain Appay; Thomas Graillon; Warren Mason; Antoine F Carpentier; Alba A Brandes; L 'Houcine Ouafik; Wolfgang Wick; Ania Baaziz; Julien P Gigan; Rafael J Argüello; Dominique Figarella-Branger; Olivier Chinot; Emeline Tabouret
Journal:  Acta Neuropathol Commun       Date:  2022-01-03       Impact factor: 7.801

Review 4.  Effects of oncolytic viruses and viral vectors on immunity in glioblastoma.

Authors:  Penghao Liu; Yaning Wang; Wenbin Ma; Yu Wang; Yuekun Wang; Ziren Kong; Wanqi Chen; Jiatong Li; Wenlin Chen; Yuanren Tong
Journal:  Gene Ther       Date:  2020-11-15       Impact factor: 5.250

5.  GBM-Targeted oHSV Armed with Matrix Metalloproteinase 9 Enhances Anti-tumor Activity and Animal Survival.

Authors:  Paola Sette; Nduka Amankulor; Aofei Li; Marco Marzulli; Daniela Leronni; Mingdi Zhang; William F Goins; Balveen Kaur; Chelsea Bolyard; Timothy P Cripe; Jianhua Yu; E Antonio Chiocca; Joseph C Glorioso; Paola Grandi
Journal:  Mol Ther Oncolytics       Date:  2019-10-24       Impact factor: 7.200
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.